A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Launched by SWEDISH ORPHAN BIOVITRUM · May 23, 2017
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called pacritinib to see how well it works for patients with specific types of myelofibrosis, which is a serious blood disorder that affects bone marrow. The trial is looking for adult patients who have low platelet counts (less than 50,000/μL) and notable symptoms related to their condition. About 399 participants will be enrolled, with two-thirds receiving pacritinib and one-third receiving other treatments chosen by their doctors.
To be eligible for the trial, participants must be at least 18 years old, have a confirmed diagnosis of myelofibrosis, and meet certain health criteria, such as having a specific level of platelet count and showing significant symptoms like pain or discomfort. Those who qualify will take the medication for a set period and will have regular check-ups to monitor their health and response to treatment. It's also important to know that participants will need to consent to the study and may be required to undergo tests like MRIs or CT scans during the trial. This study is currently recruiting participants, and it aims to provide new insights into treating myelofibrosis effectively.
Gender
ALL
Eligibility criteria
- • Diagnosis and Inclusion Criteria
- • 1. Primary MF, post-polycythemia vera MF, or post-essential thrombocythemia MF (as defined by Tefferi and Vardiman 2008
- • 2. Platelet count of \<50,000/μL at Screening (Day -35 to Day -3)
- • 3. Dynamic International Prognostic Scoring System Intermediate-1, Intermediate-2, or High-Risk (Passamonti et al 2010
- • 4. Palpable splenomegaly ≥5 cm below the lower costal margin (LCM) in the midclavicular line as assessed by physical examination
- • 5. TSS of ≥10 on the MPN-SAF TSS 2.0 or a single symptom score of ≥5 or two symptoms of ≥3, including only the symptoms of left upper quadrant pain, bone pain, itching, or night sweats.The TSS criteria need only to be met on a single day.
- • 6. Age ≥18 years
- • 7. Eastern Cooperative Oncology Group performance status 0 to 2
- • 8. Peripheral blast count of \<10% throughout the Screening period prior to randomization
- • 9. Absolute neutrophil count of ≥500/µL
- • 10. Left ventricular cardiac ejection fraction of ≥50% by echocardiogram or multigated acquisition scan
- • 11. Adequate liver and renal function, defined by liver transaminases (aspartate aminotransferase \[AST\]/serum glutamic-oxaloacetic transaminase \[SGOT\] and alanine aminotransferase \[ALT\]/serum glutamic pyruvic transaminase \[SGPT\]) ≤3 × the upper limit of normal (ULN) (AST/ALT ≤5 × ULN if transaminase elevation is related to MF), total bilirubin ≤4 x ULN (in cases where total bilirubin is elevated, direct bilirubin ≤4 × ULN, is required) and creatinine ≤2.5 mg/dL
- • 12. Adequate coagulation defined by prothrombin time/international normalized ratio and partial thromboplastin time ≤1.5 × ULN
- • 13. If fertile, willing to use highly effective birth control methods during the study
- • 14. Willing to undergo and able to tolerate frequent MRI or CT scan assessments during the study
- • 15. Able to understand and willing to complete symptom assessments using a patient-reported outcome instrument
- • 16. Provision of signed informed consent
- • Exclusion Criteria
- • 1. Life expectancy \<6 months
- • 2. Completed allogeneic stem cell transplant (allo-SCT) or are eligible for and willing to complete other approved available therapy including allogeneic stem cell
- • 3. History of splenectomy or planning to undergo splenectomy
- • 4. Splenic irradiation within the last 6 months
- • 5. Previously treated with pacritinib
- • 6. Treatment with any MF-directed therapy within 14 days prior to treatment Day 1
- • 7. Prior treatment with more than one JAK2 inhibitor
- 8. Prior treatment with with ruxolitinib, if BOTH of the following conditions are met:
- • i. exposure to higher-dose ruxolitinib (\>10 mg daily) within 120 days prior to treatment Day 1 AND ii. total duration of treatment with higher-dose ruxolitinib (\>10 mg daily) was \>90 days, from first to last exposure (i.e., this 90-day period starts on the date of first administration of ruxolitinib at a total daily dose of \>10 mg and continues for 90 calendar days, regardless of whether higher-dose ruxolitinib is administered continuously or intermittently).
- • 9. Prior treatment with any JAK2 inhibitor other than ruxolitinib, irrespective of dose, with a duration of \>90 days. The 90-day period starts on the date of first administration of JAK2 inhibitor therapy and continues for 90 calendar days, regardless of whether therapy is administered continuously or intermittently.
- • 10. Treatment with an experimental therapy, including MF-directed experimental therapies within 28 days prior to treatment Day 1
- • 11. Systemic treatment with a strong CYP 3A4 inhibitor or a strong CYP 3A4 inducer within 14 days prior to treatment Day 1. Shorter washout periods may be permitted with approval of the Medical Monitor, provided that the washout period is at least five half-lives of the drug prior to treatment Day 1
- • 12. Significant recent bleeding history defined as National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2 within 3 months prior to treatment Day 1, unless precipitated by an inciting event (eg, surgery, trauma, or injury)
- • 13. Systemic treatment with medications that increase the risk of bleeding, including anticoagulants, antiplatelet agents (except for aspirin dosages of ≤100 mg per day),and daily use of cyclooxygenase-1 (COX-1) inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to treatment Day 1. Treatment with systemic anti-vascular endothelial growth factor (anti-VEGF) agents within 28 days prior to treatment Day 1.
- • 14. Systemic treatment with medications that can prolong the QT interval within 14 days prior to treatment Day 1. Shorter washout periods may be permitted with approval of the Medical Monitor, provided that the washout period is at least five half-lives of the drug prior to treatment Day 1
- • 15. Any history of CTCAE grade ≥2 non-dysrhythmia cardiac conditions within 6 months prior to treatment Day 1. Patients with asymptomatic grade 2 non-dysrhythmia cardiovascular conditions may be considered for inclusion, with the approval of the Medical Monitor, if stable and unlikely to affect patient safety.
- • 16. Any history of CTCAE grade ≥2 cardiac dysrhythmias within 6 months prior to treatment Day 1. Patients with non-corrected QT interval CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the Medical Monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety.
- • 17. QT corrected by the Fridericia method (QTcF) prolongation \>450 ms or other factors that increase the risk for QT interval prolongation (eg, hypokalemia \[defined as serum potassium \<3.0 mEq/L that is persistent and refractory to correction\], or history of long QT interval syndrome).
- • 18. New York Heart Association Class II, III, or IV congestive heart failure
- • 19. Any active gastrointestinal or metabolic condition that could interfere with absorption of oral medication
- • 20. Active or uncontrolled inflammatory or chronic functional bowel disorder such as Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation
- • 21. Other malignancy within 3 years prior to treatment Day 1. The following patients may be eligible despite having had a malignancy within the prior 3 years: patients with curatively treated squamous or basal cell carcinoma of the skin; patients with curatively treated non-invasive cancers; patients with organ-confined prostate cancer with prostate specific antigen (PSA) \<20 ng/mL and National Comprehensive Cancer Network risk of Very Low, Low, or Favorable Intermediate; and patients with curatively treated non-metastatic prostate cancer with negative PSA.
- • 22. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection, psychiatric illness, or social situation that, in the judgment of the treating physician, would limit compliance with study requirements
- • 23. Known seropositivity for human immunodeficiency (HIV) virus. For patients in France, Czech Republic, and Italy only: testing for HIV is required during Screening.
- • 24. Known active hepatitis A, B, or C virus infection. For patients in France, Czech Republic and Italy only: testing for hepatitis B and C is required during Screening.
- • 25. Women who are pregnant or lactating
- • 26. Concurrent enrollment in another interventional trial
- • 27. Severe thrombocytopenia due to vitamin B12 deficiency, folate deficiency, or viral infection in the opinion of the investigator
- • 28. Known hypersensitivity to pacritinib or any of the following inactive ingredients: microcrystalline cellulose, polyethylene glycol, and magnesium stearate; any contraindication to the "physician's choice" medicinal product selected by the investigator to be used as the comparator or to loperamide or equivalent antidiarrheal medication
- • 29. Persons deprived of their liberty by a judicial or administrative decision
- • 30. Persons subject to legal protection measures or unable to express their consent
- • 31. Temporarily incapacitated persons
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum (Sobi) is a leading global biopharmaceutical company dedicated to developing and delivering innovative therapies for rare diseases and complex conditions. With a strong focus on hematology, immunology, and genetic disorders, Sobi leverages advanced research and development capabilities to provide life-changing treatments for patients in need. The company is committed to sustainability and collaboration, working closely with healthcare professionals, patient organizations, and regulatory authorities to enhance patient outcomes and improve quality of life. Sobi's extensive portfolio includes both proprietary and partnered products, reflecting its dedication to addressing unmet medical needs in the rare disease community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Baltimore, Maryland, United States
Cleveland, Ohio, United States
Seattle, Washington, United States
Chicago, Illinois, United States
Hackensack, New Jersey, United States
Chicago, Illinois, United States
Grand Rapids, Michigan, United States
Duarte, California, United States
Rochester, New York, United States
Columbus, Ohio, United States
Cleveland, Ohio, United States
Portland, Oregon, United States
Edmonton, Alberta, Canada
Weston, Florida, United States
Pittsburgh, Pennsylvania, United States
New York, New York, United States
Aurora, Colorado, United States
Washington, District Of Columbia, United States
New Haven, Connecticut, United States
Phoenix, Arizona, United States
Los Angeles, California, United States
Baltimore, Maryland, United States
Bucharest, , Romania
Houston, Texas, United States
Madrid, , Spain
Durham, North Carolina, United States
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
New York, New York, United States
Sydney, New South Wales, Australia
Chicago, Illinois, United States
New Orleans, Louisiana, United States
Seoul, , Korea, Republic Of
Busan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Brno, , Czechia
Seoul, , Korea, Republic Of
Westwood, Kansas, United States
Columbus, Ohio, United States
Los Angeles, California, United States
Fukushima, , Japan
Miyazaki, , Japan
Tokyo, , Japan
Tokyo, , Japan
Tokyo, , Japan
Bucharest, , Romania
Toronto, Ontario, Canada
Kraków, , Poland
Paris, , France
Madrid, , Spain
Pamplona, , Spain
Washington, District Of Columbia, United States
Salt Lake City, Utah, United States
Fukuoka, , Japan
Manchester, , United Kingdom
Tsu, , Japan
Florence, , Italy
Oxford, , United Kingdom
Kaposvár, , Hungary
Busan, , Korea, Republic Of
Olomouc, , Czechia
Gloucester, , United Kingdom
Toronto, Ontario, Canada
Miyagi, , Japan
Sofia, , Bulgaria
Varna, , Bulgaria
Seoul, , Korea, Republic Of
Gomel, , Belarus
Porto Alegre, Rio Grande Do Sul, Brazil
Saint John's, Newfoundland And Labrador, Canada
Barcelona, , Spain
Plovdiv, , Bulgaria
Volgograd, , Russian Federation
Grodno, , Belarus
Novi Sad, , Serbia
Salvador, Bahia, Brazil
Banja Luka, , Bosnia And Herzegovina
Bethesda, Maryland, United States
Saint Louis, Missouri, United States
Strasbourg, , France
Pessac, , France
Barcelona, , Spain
San Antonio, Texas, United States
Monza, , Italy
Edmonton, Alberta, Canada
Birmingham, Alabama, United States
Boulder, Colorado, United States
Bethesda, Maryland, United States
Columbia, Maryland, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Las Vegas, Nevada, United States
Commack, New York, United States
New York, New York, United States
Nashville, Tennessee, United States
San Antonio, Texas, United States
Melbourne, Victoria, Australia
Perth, Western Australia, Australia
Minsk, , Belarus
Pleven, , Bulgaria
Sofia, , Bulgaria
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Halifax, Nova Scotia, Canada
Montreal, Quebec, Canada
Pilsen, , Czechia
Prague, , Czechia
Amiens, , France
Nîmes, , France
Pierre Benite, , France
Poitiers, , France
Toulouse, , France
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Cologne, , Germany
Halle, , Germany
Minden, , Germany
Munich, , Germany
Ulm, , Germany
Budapest, , Hungary
Debrecen, , Hungary
Kecskemét, , Hungary
Nyíregyháza, , Hungary
Székesfehérvár, , Hungary
Haifa, , Israel
Jerusalem, , Israel
Kfar Saba, , Israel
Petah Tikva, , Israel
Tel Aviv, , Israel
Bari, , Italy
Bologna, , Italy
Forlì, , Italy
Palermo, , Italy
Pavia, , Italy
Rimini, , Italy
Rome, , Italy
Varese, , Italy
Gdańsk, , Poland
Rzeszów, , Poland
Toruń, , Poland
Warsaw, , Poland
Wrocław, , Poland
łódź, , Poland
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Pyatigorsk, , Russian Federation
Saint Petersburg, , Russian Federation
Saint Petersburg, , Russian Federation
Saint Petersburg, , Russian Federation
Samara, , Russian Federation
Ufa, , Russian Federation
Belgrade, , Serbia
Barcelona,, , Spain
Murcia, , Spain
Salamanca, , Spain
Valencia, , Spain
Cherkasy, , Ukraine
Dnipro, , Ukraine
Ivano Frankivs'k, , Ukraine
Kharkiv, , Ukraine
Kyiv, , Ukraine
Kyiv, , Ukraine
Kyiv, , Ukraine
Lviv, , Ukraine
Poltava, , Ukraine
Sheffield, South Yorkshire, United Kingdom
Glasgow, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Seville, , Spain
Lublin, , Poland
Tōon, , Japan
Bengaluru, , India
Turin, , Italy
Tbilisi, , Georgia
Chandigarh, , India
Udine, , Italy
Saint John's, Newfoundland And Labrador, Canada
Brescia, , Italy
Tbilisi, , Georgia
Katowice, , Poland
Braşov, , Romania
Cluj Napoca, , Romania
Nowy Sącz, , Poland
Marseille, , France
Milan, , Italy
Katowice, , Poland
Novara, , Italy
Sarajevo, , Bosnia And Herzegovina
Naples, , Italy
Madrid, , Spain
Białystok, , Poland
Rome, , Italy
Pune, Maharashtra, India
Calgary, Alberta, Canada
Vancouver, British Columbia, Canada
Halifax, Nova Scotia, Canada
Montreal, Quebec, Canada
Guwahati, Assam, India
Jaipur, Rajasthan, India
Kolkata, West Bengal, India
Aktobe, , Kazakhstan
Almaty, , Kazakhstan
Karaganda, , Kazakhstan
Shymkent, , Kazakhstan
Fortaleza, Ceara, Brazil
Goiana, Goias, Brazil
Belo Horizonte, Minas Gerais, Brazil
Curitiba, Parana, Brazil
Mossoró, Rio Grande Do Norte, Brazil
Porto Alegre, Rio Grande Do Sul, Brazil
Florianópolis, Santa Catarina, Brazil
Campinas, Sao Paulo, Brazil
Jaú, Sao Paulo, Brazil
São Paulo, Sao Paulo, Brazil
São Paulo, Sao Paulo, Brazil
São Paulo, Sao Paulo, Brazil
Rio De Janeiro, , Brazil
Sūrat, Gujarat, India
Gurgaon, Haryana, India
Madurai, Tamil Nadu, India
Hyderabad, Telangana, India
Dehradun, Uttarakhand, India
Kolkata, West Bengal, India
Delhi, , India
Chuo, , Japan
Astana, , Kazakhstan
Astana, , Kazakhstan
Ust Kamenogorsk, , Kazakhstan
Patients applied
Trial Officials
Simran Singh
Study Director
Sobi, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials